TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
Anlon Healthcare Limited
AHCLSmall CapNSEBSE
Biotechnology & Drugs · Biotechnology & Drugs
₹15.86down 0.05down 0.31 percentas of 31 Aug 2026
Book value ₹4.32
Key metrics
- Market Cap
- 829.17 ₹ cr
- P/E
- 26.55 x
- P/B
- 3.67 x
- ROE
- 12.38%
- ROCE
- 17.37%
- Debt to Equity
- 0.19 x
- Net Margin
- 16.58%
- Dividend Yield
- —
- Revenue Growth (YoY)
- 162.94%
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- ROCE above 20% in 1 of the last 3 financial years (2023-2024, 2024-2025, 2025-2026).
- Revenue declined year-on-year in 1 of the last 3 years.
- Net margin declined year-on-year in 1 of the last 3 years.
- Promoter holding 52.7% (pledge data not available).
- Debt-to-equity 0.19 — above the Biotechnology & Drugs median of 0.04.
AHCL
₹15.86down 0.31 percent
EOD Synced: 31 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatStable Return Franchise
17.37%ROCE
ROE: 12.38%·P/B: 3.67x
2. Forensic Health & SolvencyPiotroski 5/9 · Adequate Health
5/9Piotroski Score
Altman: 7.6 (Safe Zone)
3. Valuation & DCF Spread-30.6% Valuation Premium
₹11DCF Fair Value
CMP: ₹15.9
4. Ownership & GovernanceClean Promoter Holding
52.68%Promoter Stake
Pledged: 0.0%·Inst: —
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #9 of 35 in Biotechnology & DrugsQVGM 67/100
Quality (Q)60
ROE, ROCE, Margins & Cash Conversion
Value (V)56
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)76
3Y Sales & EPS Compounded Growth
Momentum (M)79
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #9 of 35 in Biotechnology & Drugs
Valuation
Moderate56/100
P/E Ratio:26.55x
P/B Ratio:3.67x
Dividend Yield:0.00%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Strong76/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Moderate60/100
ROE:12.4%
ROCE:17.4%
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Moderate56/100
Piotroski F-Score:5/9
Altman Z-Score:7.58
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Strong79/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹9.10
From 52W High-5.93%
52-Week High₹16.86
Valuation MultiplesCash Flow & Yield
PEG Ratio0.35
Earnings Yield3.78%
Price / FCF—
FCF Yield-13.98%
Payout Ratio—
Net-Net Ratio19.84
Solvency & SafetyPiotroski & Altman
Piotroski F-Score5/9
Altman Z-Score7.58
Graham Number₹7.64
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▲ +1.35%
DII Stake:—
OPM Margin:▲ +1.49%
Net Margin:▼ 0.48%
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | ▲ +72.06% | ▲ +162.94% | 42.96% | 15.07% | — |
| Net Profit Growth | ▼ 36.57% | ▲ +87.61% | 38.94% | 69.83% | — |
| EPS Growth | ▼ 91.92% | ▲ +128.57% | 53.85% | 76.03% | — |
Intrinsic Valuation Models & DCF Sensitivity
Institutional DCF & Intrinsic Valuation Studio — AHCL
2-Stage Discounted Cash Flow, Reverse DCF Implied Growth, and Benjamin Graham & Peter Lynch valuation benchmarks.
DCF Intrinsic Fair Value
₹12.3
Verdict:Overvalued (-22.5%)
Benjamin Graham Number
₹7.7
-51.8% vs CMPPeter Lynch Fair Value
₹30.0
+89.2% vs CMPReverse DCF Implied Growth
40.9% CAGR
Aggressive Expectations (Priced for Perfection)Valuation Spectrum PositioningCMP: ₹15.9
₹0 (Distress)CMP: ₹16DCF: ₹12Graham: ₹8
Scenario Calibration & Sensitivity Levers
Tune Discount Rate (WACC), 5-Year Growth, and Terminal Value to model bear, base, and bull cases.
Discount Rate (WACC)11.5%
Cost of Capital Hurdle
5-Year FCF Growth CAGR30.0%
Assumed stage-1 cash flow expansionTerminal Growth Rate4.5%
Long-term perpetual GDP growth rate5-Year Projected Cash Flow Schedule (₹ Cr)
| Projection Period | Growth Rate | Projected FCF | Discount Factor | Present Value |
|---|---|---|---|---|
| Year 1 | 30% | ₹22 | 0.8969 | ₹20 |
| Year 2 | 30% | ₹29 | 0.8044 | ₹23 |
| Year 3 | 30% | ₹38 | 0.7214 | ₹27 |
| Year 4 | 30% | ₹49 | 0.6470 | ₹32 |
| Year 5 | 30% | ₹64 | 0.5803 | ₹37 |
2D Sensitivity Matrix (WACC vs Terminal Growth Rate)
Click any cell to apply WACC & terminal growth scenario. Values in ₹ / share.| WACC \ g(Terminal) | 3.0% | 4.0% | 4.5% | 5.0% | 6.0% |
|---|---|---|---|---|---|
| 10.0% | ₹13 -18% | ₹15 -6% | ₹16 +2% | ₹18 +11% | ₹22 +37% |
| 11.0% | ₹11 -30% | ₹13 -21% | ₹13 -16% | ₹14 -9% | ₹17 +7% |
| 11.5% | ₹10 -35% | ₹12 -27% | ₹12 -22% | ₹13 -17% | ₹15 -3% |
| 12.0% | ₹10 -39% | ₹11 -32% | ₹11 -28% | ₹12 -24% | ₹14 -12% |
| 13.0% | ₹8 -46% | ₹9 -41% | ₹10 -38% | ₹10 -35% | ₹12 -27% |
Discounted cash flow (DCF) and valuation models are quantitative projections based on user-supplied assumptions — not a forecast, not a guarantee of future performance, and not SEBI-registered investment advice. Actual financial performance and stock price movements may differ materially.
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E26.55current
ReportedComputed, approximate
P/B3.67current
ReportedComputed, approximate
The dashed line is computed from historical close price divided by the most recently reported annual EPS or book value — not IndianAPI's own figure, which only ever gives a single current reading with no history behind it. Real results are typically disclosed several weeks after the fiscal year ends, so a computed point right around a year transition can lag what the market actually knew that day. The solid line is the real reported figure.
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | 26.55 | 3.67 |
Analyst Consensus, Price Targets & Forecasts
Analyst Ratings
No analyst consensus data available for this company.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
High risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:49.54%
Analyst Price Targets
12-month forward price consensus · 20 Aug 2026
Upside: +2,811.29%
Mean Target₹461.73vs CMP ₹15.86
High Target₹488.61+2980.8% max upside
Low Target₹378.102284.0% downside
Median Target₹458.7445 estimates
Low: ₹378.10Mean: ₹461.73High: ₹488.61
Mean Target Current Price (₹15.86)
Price targets are third-party analyst estimates compiled from institutional brokers. They do not constitute investment advice.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2027E11 Analysts
Mean Estimate
₹0.16
Low:—
High:—
FY2027E11 Analysts
Mean Estimate
₹0.17
Low:—
High:—
FY2027E11 Analysts
Mean Estimate
₹0.18
Low:—
High:—
FY2027E11 Analysts
Mean Estimate
₹0.19
Low:—
High:—
FY2028E11 Analysts
Mean Estimate
₹0.19
Low:—
High:—
FY2028E11 Analysts
Mean Estimate
₹0.20
Low:—
High:—
FY2028E11 Analysts
Mean Estimate
₹0.21
Low:—
High:—
FY2028E11 Analysts
Mean Estimate
₹0.22
Low:—
High:—
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2027 Forecast | ₹0.16 | — | — | 11 |
| FY2027 Forecast | ₹0.17 | — | — | 11 |
| FY2027 Forecast | ₹0.18 | — | — | 11 |
| FY2027 Forecast | ₹0.19 | — | — | 11 |
| FY2028 Forecast | ₹0.19 | — | — | 11 |
| FY2028 Forecast | ₹0.20 | — | — | 11 |
| FY2028 Forecast | ₹0.21 | — | — | 11 |
| FY2028 Forecast | ₹0.22 | — | — | 11 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Accounting Health & Governance Quality Radar
Algorithmic accounting analysis across balance sheet solvency, cash conversion efficiency, and ownership stability.
Governance Watchouts Flagged
Financial Strengths & Catalysts
6 Factors- •Company has a solid 3-year average ROE of 27.9%.
- •Company maintains conservative leverage with D/E of 0.19x.
- •Company has reduced borrowings by 34.4% over the last fiscal year.
- •Company has demonstrated healthy revenue growth of 15.1% CAGR over 3 years.
- •Net profit has grown at an impressive 69.8% CAGR over 3 years.
- •High promoter holding of 52.7% with zero encumbrance / pledge.
Risk Factors & Watchouts
2 Watchouts- •Cash conversion lag: Operating Cash Flow is below 50% of reported Net Profit.
- •Persistent negative operating cash flow despite reported positive accounting profits.
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score5 / 9
● Moderate (Neutral)
Altman Z-Score7.58
● Safe Zone
Negligible risk of financial distress over the next 2 years.
Beneish M-Score-1.05
● Elevated Manipulation Risk
Financial patterns show abnormal accruals or margin distortion.
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
Accounting Flow:
Wall Street Cash Flow & Free Cash Flow (FCF) Cascade
FY26 (2025-2026)3-Stage institutional flow from reported earnings to owner Free Cash Flow and capital allocation
FCF Conversion Rate (FCF / PAT)
-406.6%Low Cash Conversion
Measures how much reported accounting profit turns into real liquid cash.
Free Cash Flow Margin
-67.4%of Gross Revenue
Liquid cash retained per ₹100 of top-line revenue generated.
CapEx Reinvestment Rate
—of Operating Cash
Portion of operating cash reinvested in future capacity and maintenance.
Reported Net Profit (PAT)₹29 CrInflow
29
+ D&A Non-Cash Charge₹2 CrAdd-back
2
Working Capital Adjustment-₹109 Cr- Tied Up
109
= Operating Cash Flow (CFO)-₹79 CrOperating Cash
79
- Capital Expenditures (CapEx)-₹36 CrReinvestment
36
= Free Cash Flow (FCF)-₹116 CrFree Cash Flow
116
- Dividends & Debt Repayment-₹6 CrCapital Return
6
= Net Change in Cash-₹122 CrNet Balance
122
Multi-Year Historical FCF vs Reported PAT Trajectory:
Free Cash Flow (FCF) Reported Net Profit (PAT)
| Metric | 2021-202231 Mar 2022 | 2022-202331 Mar 2023 | 2023-202431 Mar 2024 | 2024-202531 Mar 2025 | 2025-202631 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | ₹57.14 | ₹112.88 | ₹66.58 | ₹120.29 | ₹171.97 |
| Operating profit | ₹3.58 | ₹10.93 | ₹13.61 | ₹30.57 | ₹46.27 |
| OPM | 6.27% | 9.68% | 20.44% | 25.41% | 26.91% |
| Net profit | ₹-0.11 | ₹5.82 | ₹9.66 | ₹20.52 | ₹28.51 |
| EPS | 0.00 | 0.11 | 0.18 | 0.39 | 0.60 |
| Net margin | -0.19% | 5.16% | 14.51% | 17.06% | 16.58% |
| ROE | -7.10% | 78.97% | 45.93% | 25.52% | 12.38% |
| ROCE | 6.38% | 16.07% | 17.47% | 25.21% | 17.37% |
| Debt / equity | 40.25 | 9.54 | 3.86 | 0.83 | 0.19 |
Compounded growth (CAGR)
| Metric | 1Y | 3Y |
|---|---|---|
| Revenue | 42.96% | 15.07% |
| Net profit | 38.94% | 69.83% |
| EPS | 53.85% | 76.03% |
Each column only appears when 5 real reported years actually support it — never extrapolated from fewer.
Balance sheet
| Metric | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|
| Total assets | ₹84.97 | ₹111.55 | ₹128.00 | ₹181.30 | ₹373.97 |
| Total liabilities | ₹83.42 | ₹104.17 | ₹106.97 | ₹100.88 | ₹143.74 |
| Total equity | ₹1.55 | ₹7.37 | ₹21.03 | ₹80.42 | ₹230.23 |
| Total debt | ₹62.38 | ₹70.32 | ₹81.25 | ₹66.55 | ₹43.65 |
| Cash | ₹1.54 | ₹0.62 | ₹2.27 | ₹1.45 | ₹4.37 |
| Current assets | ₹57.74 | ₹85.81 | ₹100.70 | ₹158.48 | ₹308.26 |
| Current liabilities | ₹28.89 | ₹43.55 | ₹50.10 | ₹60.05 | ₹107.57 |
| Inventory | ₹26.69 | ₹26.97 | ₹41.71 | ₹50.26 | ₹113.16 |
| Receivables | ₹20.30 | ₹43.81 | ₹38.73 | ₹75.00 | ₹103.68 |
| Payables | ₹15.23 | ₹25.33 | ₹19.99 | ₹19.64 | ₹42.19 |
| Net PP&E | ₹27.23 | ₹25.74 | ₹27.30 | ₹22.82 | ₹57.71 |
| Retained earnings | ₹-10.45 | ₹-4.63 | ₹5.03 | ₹40.57 | ₹177.08 |
Cash flow
| Metric | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|
| Operating cash flow | ₹-1.75 | ₹-2.85 | ₹-3.23 | ₹-22.55 | ₹-79.44 |
| Capital expenditure | ₹-0.48 | ₹-0.37 | ₹-3.53 | ₹-0.53 | ₹-36.47 |
| Free cash flow | ₹-2.23 | ₹-3.22 | ₹-6.76 | ₹-23.08 | ₹-115.91 |
| OCF / net profit | 15.91 | -0.49 | -0.33 | -1.10 | -2.79 |
| FCF / Capex intensity | 0.84 | 0.33 | 5.30 | 0.44 | 21.21 |
Income statement detail
| Metric | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|
| Gross profit | ₹12.57 | ₹22.98 | ₹30.82 | ₹44.55 | ₹63.10 |
| Cost of revenue | ₹44.57 | ₹89.90 | ₹35.77 | ₹75.74 | ₹108.87 |
| EBITDA | ₹5.42 | ₹12.80 | ₹15.50 | ₹32.34 | ₹47.79 |
| Income before tax | ₹-0.11 | ₹6.99 | ₹9.75 | ₹26.89 | ₹42.51 |
| Interest expense | ₹3.88 | ₹4.00 | ₹3.80 | ₹3.49 | ₹2.81 |
| Tax expense | ₹0.00 | ₹1.17 | ₹0.09 | ₹6.37 | ₹13.42 |
| D&A | ₹1.84 | ₹1.87 | ₹1.89 | ₹1.77 | ₹1.52 |
| EBITDA margin | 9.49% | 11.34% | 23.28% | 26.89% | 27.79% |
Financial ratios
| Metric | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|
| Current ratio | 2.00 | 1.97 | 2.01 | 2.64 | 2.87 |
| Quick ratio | 1.07 | 1.35 | 1.18 | 1.80 | 1.81 |
| Interest coverage | 0.92 | 2.73 | 3.58 | 8.76 | 16.47 |
| Inventory days | 218.57 | 109.50 | 425.61 | 242.21 | 379.38 |
| Receivable days | 129.67 | 141.66 | 212.32 | 227.58 | 220.06 |
| Payable days | 124.72 | 102.84 | 203.98 | 94.65 | 141.45 |
| Cash conversion cycle | 223.52 | 148.32 | 433.96 | 375.14 | 457.99 |
| Working capital days | — | — | — | — | — |
| Fixed asset turnover | 2.10 | 4.39 | 2.44 | 5.27 | 2.98 |
| ROA | -0.13% | 5.22% | 7.55% | 11.32% | 7.62% |
| ROIC | 5.74% | 11.81% | 13.48% | 16.03% | 11.75% |
| Gross margin | 22.00% | 20.36% | 46.29% | 37.04% | 36.69% |
DuPont 3-Stage ROE Factor Decomposition
Deconstructing Return on Equity into Profitability, Asset Efficiency, and Financial Leverage
Balanced Return EngineFY2025-2026
Net marginProfitability
16.58%
Net Profit generated per ₹100 of revenue (Profitability)
×
Asset turnoverEfficiency
0.46
Revenue generated per ₹1 of total assets (Capital Efficiency)
×
Equity multiplierLeverage
1.62
Total assets supported per ₹1 of shareholder equity (Leverage)
=
Implied DuPont ROEFinal Output
12.38%
Reported: 12.38%
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 24 Apr 2026 | split | 2:10 |
| 24 Apr 2026 | bonus | 1:1 |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
Biotechnology & DrugsCompare Peers in Studio
Market Cap829.17 ₹ cr
Beats 56% of 9 industry peers · median 821.74 ₹ cr
P/E26.55 x
Beats 71% of 7 industry peers · median 21.47 x
P/B3.67 x
Beats 88% of 8 industry peers · median 1.66 x
ROE12.38%
Beats 75% of 8 industry peers · median 7.85%
ROCE17.37%
Beats 100% of 8 industry peers · median 5.30%
Debt to Equity0.19 x
Beats 63% of 8 industry peers · median 0.04 x
Net Margin16.58%
Beats 88% of 8 industry peers · median 3.95%
Revenue Growth (YoY)162.94%
Beats 100% of 8 industry peers · median 10.38%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
AstraZeneca Pharma India LimitedASTRAZEN | ₹17,813.30 | — | — |
Alembic LimitedALEMBICLTD | ₹2,540.32 | 8.09 | 1.05 |
Amrutanjan Health Care LimitedAMRUTANJAN | ₹1,491.63 | 25.67 | 4.02 |
Bajaj Healthcare LimitedBAJAJHCARE | ₹1,129.36 | 47.93 | 2.03 |
Anuh Pharma LimitedANUHPHR | ₹821.74 | 20.41 | 2.38 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Document & Filings Vault
No statutory exchange announcements or PDF filings have been recorded for AHCL yet.
News
- IndianAPIAnlon Healthcare share price trades flat after muted listing. Should you buy, sell or hold?
Anlon Healthcare IPO listing was in-line with the muted Street expectations as seen from the trends in the Anlon Healthcare IPO GMP today. Anlon Healthcare shares are listed on both the stock exchanges, BSE and NSE.
- IndianAPIAnlon Healthcare shares off to a slow start, list at just 1% premium over IPO price
Anlon Healthcare IPO listing: Shares of Anlon Healthcare were off to a slow start on Wednesday, September 3, as they debuted on a flat note in the Indian stock market. Anlon Healthcare shares listed at ₹92 on the NSE, up 1.10% over its initial public offering (IPO) price of ₹91.
- IndianAPIAnlon Healthcare IPO listing date today. GMP, experts signal muted debut of shares on Dalal Street
Anlon Healthcare IPO listing date is today. The trends in Anlon Healthcare IPO GMP today analysts signal a muted debut of shares in stock market today.
- IndianAPIAnlon Healthcare IPO to list on Wednesday; GMP signals muted debut, price and other details here
The IPO of Anlon Healthcare, which was oversubscribed 7.12 times, will list on September 3. The company, focusing on pharmaceutical intermediates, aims to use proceeds for expansion, debt repayment, and working capital. The grey market indicates that shares may see a muted debut.
- IndianAPIAnlon Healthcare IPO allotment date in focus. Latest GMP, steps to check share allotment status online
Anlon Healthcare IPO allotment date is likely today, September 1. Investors can check Anlon Healthcare IPO allotment status online through the websites of BSE and NSE, and on the official web portal of the IPO registrar. Kfin Technologies is the Anlon Healthcare IPO registrar.
- IndianAPIAnlon Healthcare IPO allotment to be fixed soon. Latest GMP, steps to check share allotment status online
Anlon Healthcare IPO allotment date is likely September 1. Investors can check Anlon Healthcare IPO allotment status online through the websites of BSE and NSE, and on the official web portal of the IPO registrar. Kfin Technologies is the Anlon Healthcare IPO registrar.
- IndianAPIAnlon Healthcare IPO subscribed over 7 times by the end of Day 3. Check GMP and other details
Anlon Healthcare's IPO closed on August 29 with strong demand, achieving 7.12 times subscription. Retail investors subscribed 47.29 times. The IPO's grey market premium is ₹2, with an estimated listing price of ₹93. Funds raised will support expansion and working capital.
- IndianAPIAnlon Healthcare IPO day 3: GMP, review to subscription status. Good or bad bet for investors? EXPLAINED
Anlon Healthcare IPO GMP: According to market observers, the company's shares are trading at a premium of ₹6 in the grey market today
- IndianAPIIPO GMPs: Vikran Engineering IPO vs Anlon Healthcare IPO — how much gain does grey market signal?
Vikran Engineering IPO received robust demand, being fully subscribed in two hours, while Anlon Healthcare IPO saw moderate interest. Grey market premiums suggest healthier listing gains for Vikran, indicating stronger investor confidence compared to Anlon, which is driven by retail demand.
- IndianAPIAnlon Healthcare IPO Day 2 Update:Issue booked 3.30x so far. Check GMP, subscription status, review, more. Apply or not?
The Anlon Healthcare IPO saw a subscription status of 1.69 times on the first day, with retail oversubscribed at 8.99 times. The price band is between ₹86 and ₹91, and the estimated listing price is ₹96, indicating strong market interest.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.